The Colloids and Biological Interfaces (CBIO) group is a multidisciplinary research group with a mission to contribute to a better health in the society by developing healthcare technologies that improve drug delivery, immunotherapy, bioimaging, and biomedical devices. The technologies are conceptualized based on decades-long experience within nanoscale solutions for these purposes. To support this mission, the group brings together scientists from a range of diverse research fields and employs synthetic chemists, biophysicists, formulation scientists, cell biologists, immunologists, veterinarians, and medical doctors. This creates a unique scientific environment capable of handling research projects from initial concept and synthesis of therapeutic compounds and drug delivery systems to preclinical assessment as well as investigation of the biological context in which the new technology must function. The group is deeply dedicated to bringing health technologies into play in a clinical context and has provided the foundation for a series of spinout companies. Technologies of these spinout companies currently undergoes preclinical and clinical evaluation, or are marketed for use in humans.
Projects: